loading
X 4 Pharmaceuticals Inc stock is traded at $1.60, with a volume of 441.97K. It is down -4.76% in the last 24 hours and down -13.98% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$1.68
Open:
$1.58
24h Volume:
441.97K
Relative Volume:
0.57
Market Cap:
$9.26M
Revenue:
-
Net Income/Loss:
$-16.76M
P/E Ratio:
-20.00
EPS:
-0.08
Net Cash Flow:
$-132.97M
1W Performance:
-12.09%
1M Performance:
-13.98%
6M Performance:
-92.38%
1Y Performance:
-93.13%
1-Day Range:
Value
$1.55
$1.71
1-Week Range:
Value
$1.55
$2.22
52-Week Range:
Value
$1.38
$26.83

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name
Name
X 4 Pharmaceuticals Inc
Name
Phone
857-529-8300
Name
Address
61 NORTH BEACON STREET, BOSTON, MA
Name
Employee
143
Name
Twitter
@x4pharma
Name
Next Earnings Date
2025-03-25
Name
Latest SEC Filings
Name
XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XFOR
X 4 Pharmaceuticals Inc
1.60 12.06M 0 -16.76M -132.97M -0.08
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-23 Downgrade B. Riley Securities Buy → Neutral
Aug-30-23 Resumed B. Riley Securities Buy
Dec-22-22 Initiated Cantor Fitzgerald Overweight
Dec-12-22 Initiated Piper Sandler Overweight
Dec-23-19 Initiated Oppenheimer Outperform
Dec-18-19 Initiated ROTH Capital Buy
Dec-09-19 Upgrade Citigroup Neutral → Buy
Dec-05-19 Initiated B. Riley FBR Buy
Jun-07-19 Initiated Stifel Buy
Jun-05-19 Initiated Cowen Outperform
View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

pulisher
04:34 AM

Real time alert setup for X4 Pharmaceuticals Inc. performanceConservative Asset Allocation Risk Analysis - Newser

04:34 AM
pulisher
01:19 AM

How to use Fibonacci retracement on X4 Pharmaceuticals Inc.Free Buy Signal Based on Chart Analysis - Newser

01:19 AM
pulisher
Aug 01, 2025

Measuring X4 Pharmaceuticals Inc.’s beta against major indicesIntelligent Trade Forecast With AI Analytics - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

What is X4 Pharmaceuticals Inc. company’s growth strategyAI Powered Signals For Consistent Profits - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

Regression analysis insights on X4 Pharmaceuticals Inc. performanceChart Pattern Recognition for Profit Timing - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

Strategies to average down on X4 Pharmaceuticals Inc.Volume Based Swing Signal Prediction Map - Newser

Aug 01, 2025
pulisher
Aug 01, 2025

Is X4 Pharmaceuticals Inc. stock overvalued or undervaluedTop Growth Review With High Returns - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

Why X4 Pharmaceuticals Inc. stock attracts strong analyst attentionMarket Downturn Defense Strategy Analysis - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

When is X4 Pharmaceuticals Inc. stock expected to show significant growthAdvanced Screener Data Feed To Watch Now - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

What analysts say about X4 Pharmaceuticals Inc. stock outlookAlpha Stock Picks with Chart Confirmation - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Published on: 2025-07-31 06:46:25 - metal.it

Jul 31, 2025
pulisher
Jul 30, 2025

X4 Pharmaceuticals Inc. stock chart pattern explainedBuy Opportunity Forecast for Fast Traders - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

How to integrate X4 Pharmaceuticals Inc. into portfolio analysis toolsEntry Points For Growing Stocks Identified by Models - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 02:25:32 - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

X4 Pharmaceuticals Inc. stock trend outlook and recovery pathWeekly Stock Market Strategy Summary - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

How X4 Pharmaceuticals Inc. stock performs during market volatilityFree Access to Real-Time Trade Insights - Newser

Jul 30, 2025
pulisher
Jul 29, 2025

X4 Pharmaceuticals Inc. stock daily chart insightsChart Scanner for Swing Trade Timing - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Real time breakdown of X4 Pharmaceuticals Inc. stock performanceFree Daily Smart Money Movement Monitor - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

What are analysts’ price targets for X4 Pharmaceuticals Inc. in the next 12 monthsBest Dividend Outlook For Consistent Profits - jammulinksnews.com

Jul 29, 2025
pulisher
Jul 28, 2025

What institutional investors are buying X4 Pharmaceuticals Inc. stockSuperior returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does X4 Pharmaceuticals Inc. compare to its industry peersExplosive earnings growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

India Inc Q1 Revenue Growth: 4-6% Estimate - Rediff MoneyWiz

Jul 28, 2025
pulisher
Jul 27, 2025

What makes X4 Pharmaceuticals Inc. stock price move sharplyUnlock expert stock analysis and alerts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Published on: 2025-07-28 06:09:24 - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive X4 Pharmaceuticals Inc. stock higher in 2025Unlock expert insights for smarter investing - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for X4 Pharmaceuticals Inc.Build wealth steadily with proven strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Has X4 Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewFree Stock Tips Group - Newser

Jul 27, 2025
pulisher
Jul 25, 2025

Why X4 Pharmaceuticals Inc. stock is on top investor watchlistsFree Capital Allocation Plans - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Layoff Tracker: Flagship Unicorns Tessera, Generate:Biomedicines Downsize - BioSpace

Jul 24, 2025
pulisher
Jul 24, 2025

Fierce Biotech Layoff Tracker 2025: Rocket ejects 30% of staffers; Flagship's Tessera and Generate Bio trim teams - Fierce Biotech

Jul 24, 2025
pulisher
Jul 23, 2025

X4 Pharmaceuticals Inc. Stock Analysis and ForecastFree Investment Community - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is X4 Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025

X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Baldry Mark
Chief Commercial Officer
Nov 15 '24
Buy
0.34
13,404
4,598
129,173
Ragan Paula
President and CEO
Jan 24 '25
Sale
0.45
76,473
34,719
1,087,386
Mostafa Adam S.
Chief Financial Officer
Jan 24 '25
Sale
0.45
74,773
33,947
0
Baldry Mark
Chief Commercial Officer
Jan 24 '25
Sale
0.45
29,159
13,241
94,123
DiBiase Mary
Chief Operating Officer
Jan 24 '25
Sale
0.45
22,258
10,094
490,980
Arbet-Engels Christophe
Chief Medical Officer
Jan 24 '25
Sale
0.45
11,624
5,284
14,207
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Cap:     |  Volume (24h):